Contraindicated (one)bortezomib will boost the degree or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or reasonable CYP2C19 inhibitors may perhaps improve mavacamten systemic exposure, leading to heart failure as a consequence of systolic dysfunction. B: Could be satisfactory. Either animal reports exhibit no possibility but human https://shanegarnh.blogdeazar.com/26871594/the-smart-trick-of-anisperimus-that-no-one-is-discussing